• MediWound posted Q1 revenue of USD 1.5 million, down 62.7% year over year.
• Net loss widened to USD 3 million, or USD 0.23 per share.
• Operating loss deepened to USD 8 million; R&D spending climbed to USD 5.2 million as EscharEx Phase III costs rose.
• Cash, cash equivalents, and deposits fell to USD 45 million as of March 31 from USD 54 million at year-end.
• EscharEx Phase III VALUE trial enrollment continued; interim sample-size reassessment and enrollment completion targeted by end of Q1 2027, while 2026 revenue guidance was reaffirmed at USD 24-26 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270700PRIMZONEFULLFEED9727206) on May 27, 2026, and is solely responsible for the information contained therein.